Q3 Earnings Forecast for Longeveron Issued By Zacks Research

Longeveron Inc. (NASDAQ:LGVN) – Equities research analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Longeveron in a report issued on Thursday, August 13th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of ($0.17) per share for the quarter, down from their previous estimate of ($0.16). The consensus estimate for Longeveron’s current full-year earnings is ($0.68) per share. Zacks Research also issued estimates for Longeveron’s Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.56) EPS.

Longeveron (NASDAQ:LGVN) last announced its earnings results on Wednesday, August 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01). Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%.The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.33 million.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings cut shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. HC Wainwright dropped their price objective on Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, May 4th. Maxim Group cut shares of Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Wall Street Zen cut Longeveron from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Longeveron Trading Up 4.5%

LGVN stock opened at $0.82 on Thursday. The stock has a market cap of $25.61 million, a PE ratio of -0.83 and a beta of -0.31. Longeveron has a 1 year low of $0.47 and a 1 year high of $1.23. The stock has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $0.77.

Institutional Trading of Longeveron

An institutional investor recently bought a new stake in Longeveron stock. XTX Topco Ltd purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent quarter. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.